Program
irinotecan sucrosofate
Also written as “Irinotecan liposome injection”, “PEP02” and “Irinotecan Liposome Injection”.
Its studies are mostly in Pancreatic Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Esophageal Squamous Cell Carcinoma · Cholangiocarcinoma, led by 9 companies.
Drug pageIrinotecan sucrosofate: every studyMany companies study it; this page follows only the 20 they lead. All 79 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 50 open or running | phase 2since Jan 18, 2021 | Jul 20, 2020 | none ahead |
| PharmaEngineits history only | 50 open or running | phase 2since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Ipsenits history only | 40 open or running | phase 3since Mar 9, 2017 | Dec 19, 2012 | none ahead |
| Cardiff Oncologyits history only | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Sep 29, 2021 | Sep 29, 2021 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Shanghai Runshi Pharmaceutical Technologyits history only | 11 open or running | phase 2since Jul 9, 2024 | Jul 9, 2024 | none ahead |
| SONIRE Therapeuticsits history only | 11 open or running | early phase 1since Jun 5, 2025 | Jun 5, 2025 | Dec 1, 2026early phase 1 · NCT07033689 |
| Sorrento Therapeuticsits history only | 10 open or running | phase 3since Jul 26, 2019 | Jul 26, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 18, 2008.
- Sep 10, 2015Phase 2 study in Pancreatic NeoplasmsIpsen · NCT02551991 · 56 enrolled · United States, Australia, Spain
- Aug 12, 2016Phase 1 study in Solid TumorPharmaEngine · NCT02884128 · 16 enrolled
- Mar 9, 2017Phase 3 study in Small Cell Lung CarcinomaIpsen · NCT03088813 · 491 enrolled · United States, Australia, Belgium and more
- Dec 21, 2018Phase 1 study in Refractory Solid TumorsPharmaEngine · NCT03810742 · 44 enrolled · Taiwan
- Jul 26, 2019Sorrento Therapeutics’ first study: phase 3 study in Malignant Tumor of Pancreas Metastatic to LiverNew to Sorrento TherapeuticsSorrento Therapeutics · NCT04037241
- Jul 20, 2020CSPC Pharmaceutical Group’s first study: phase 1 study in Advanced Pancreatic CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04482257 · 48 enrolled · China
- Jan 18, 2021Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT04728035 · 119 enrolled · China
- Jan 18, 2021Phase 2 study in Small Cell Lung CarcinomaCSPC Pharmaceutical Group · NCT04727853 · 66 enrolled · China
- Feb 9, 2021Cardiff Oncology’s first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
- Aug 4, 20212 phase 2 studiesCSPC Pharmaceutical Group · NCT05009953, NCT05047991
- Sep 29, 2021Jiangsu HengRui Medicine’s first study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05086822 · 32 enrolled · China
- May 3, 2022Phase 1 study in Metastatic Pancreatic AdenocarcinomaIpsen · NCT05383352 · 177 enrolled · Australia, France, Germany and more
- Jul 9, 2024Shanghai Runshi Pharmaceutical Technology’s first study: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06512428 · 138 planned · China
- Jun 5, 2025SONIRE Therapeutics’ first study: early phase 1 study in Pancreatic NeoplasmsNew to SONIRE TherapeuticsSONIRE Therapeutics · NCT07033689 · 10 planned · United States
Ahead
- Dec 1, 2026Primary completion: early phase 1 study in Pancreatic NeoplasmsSONIRE Therapeutics · NCT07033689
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Topotecanrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07033689Pancreatic Neoplasms · United States | Early 1 | Recruiting | SONIRE Therapeutics | Dec 1, 2026 | 10 |
| NCT06512428Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Shanghai Runshi Pharmaceutical Technology | Jan 30, 2026 | 138 |
| NCT05383352Metastatic Pancreatic Adenocarcinoma · Australia, France, Germany and more | 1 | Completed | Ipsen | May 27, 2024 | 177 |
| NCT05086822Advanced Solid Tumors · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 28, 2017 | 32 |
| NCT05047991Pancreatic Cancer Non-resectable | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2023 | 153 |
| NCT05009953Cholangiocarcinoma · China | 2 | Terminated | CSPC Pharmaceutical Group | Jan 16, 2023 | 17 |
| NCT04752696Pancreatic Ductal Adenocarcinoma · United States | 2 | Terminated | Cardiff Oncology | Dec 24, 2024 | 41 |
| NCT04728035Advanced Breast Cancer · China | 1 | Completed | CSPC Pharmaceutical Group | Jun 5, 2023 | 119 |
| NCT04727853Small Cell Lung Carcinoma · China | 2 | Completed | CSPC Pharmaceutical Group | Apr 26, 2022 | 66 |
| NCT04482257Advanced Pancreatic Cancer · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2020 | 48 |
| NCT04037241Malignant Tumor of Pancreas Metastatic to Liver | 3 | Withdrawn | Sorrento Therapeutics | Jan 1, 2022 | 0 |
| NCT03810742Refractory Solid Tumors · Taiwan | 1 | Completed | PharmaEngine | May 4, 2022 | 44 |
| NCT03088813Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Ipsen | Feb 8, 2022 | 491 |
| NCT02884128Solid Tumor | 1 | Completed | PharmaEngine | Aug 2008 | 16 |
| NCT02551991Pancreatic Neoplasms · United States, Australia, Spain | 2 | Completed | Ipsen | Feb 15, 2021 | 56 |
| NCT01770353Triple Negative Breast Neoplasms · United States | 1 | Completed | Ipsen | Oct 2, 2018 | 45 |
| NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merrimack Pharmaceuticals | Feb 2014 | 417 |
| NCT00940758Colorectal Neoplasms · Taiwan | 1 | Completed | PharmaEngine | May 2012 | 18 |
| NCT00813163Pancreatic Neoplasms · United States, Taiwan | 2 | Completed | PharmaEngine | Dec 2010 | 41 |
| NCT00813072Stomach Neoplasms · Bosnia and Herzegovina, Croatia, Korea, Republic of and more | 2 | Completed | PharmaEngine | Jul 2010 | 135 |
How it is read
Names in the registry
- “Irinotecan liposome injection”, 5 entries
- “PEP02”, 4 entries
- “Irinotecan Liposome Injection”, 3 entries
- “MM-398”, 2 entries
- “Nanoliposomal irinotecan”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 6 studies
- Small Cell Lung Carcinoma, 2 studies
- Breast Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.